The ePlex Respiratory Pathogen (RP) Panel identifies the most common viral and bacterial organisms associated with upper respiratory infection.
On March 2, 2020, GenMark Diagnostics announced the worldwide shipment of the ePlex® SARS-CoV-2 Test*. Able to deliver rapid results, the ePlex Test can help accelerate response to a growing global public health threat.
Respiratory infections cause more doctor visits and absences from school and work than any other illness. It is estimated that ~10% of people in the U.S. and Europe are infected with influenza each year during flu season; globally resulting in about 3-5 million severe cases and 250,000-500,000 deaths every year. However, it is not just influenza that can cause respiratory infections; in addition to the flu, there are approximately 500 million non–influenza respiratory infections occurring annually.
The clinical presentation of respiratory pathogens is very similar, thus complicating proper diagnosis and appropriate therapy selection. The comprehensive design of the ePlex RP Panel may help improve patient care by identifying pathogens that are often missed by traditional methods. Accurately determining the cause of infection has been shown to reduce length of stay and time in isolation. Accurate diagnosis also improves patient cohorting and decreases the risk of hospital acquired infection.
|While many systems claim sample-to-answer capabilities, only the ePlex System is able to integrate the entire process from order-to-report to better realize the benefits of rapid, multiplex molecular diagnostics. The ePlex System is the True Sample-to-Answer Solution® because it improves overall turnaround time with end-to-end integration that includes:
|Multiple studies have shown that rapid multiplex molecular diagnostics for respiratory pathogens can help improve outcomes, reduce cost-of-care and support key quality initiatives. The ePlex system and the comprehensive ePlex RP panel provide physicians the actionable information they need to make timely treatment decisions. The ePlex System is designed to improve true turnaround time from order-to-report, with a LEAN workflow, by eliminating manual steps and staging of samples that often delay and complicate efficient test processing and result reporting.|
The True Sample-to-Answer Solution®
*ePlex® SARS-CoV-2 Test is For Research Use Only. Not for use in diagnostic procedures.
To learn more about the Respiratory Pathogen (RP) Panel or to schedule a demonstration, contact us at 1.800.373.6767 or email us.
 Johns Hopkins Medicine Health Library. http://www.hopkinsmedicine.org/healthlibrary/conditions/pediatrics/upper_respiratory_infection_uri_or_common_cold_90,P02966 (accessed February 2016)
 European Centre for Disease Prevention and Control. Seasonal Influenza. http://www.ecdc.europa.eu/en/healthtopics/seasonal_influenza/Pages/index.aspx (accessed February 2016)
 World Health Organization. (2014). Seasonal Influenza Fact Sheet 211. http://www.who.int/mediacentre/factsheets/fs211/en/
 Fendrick A, et al. (2003) The Economic Burden of Non-Influenza-Related Viral Respiratory Tract Infection in the United States. Arch Intern Med 163(4):487-94.
 Rogers, B. et al. 2015. Impact of a Rapid Respiratory Panel Test on Patient Outcomes. Archives of Pathology and Laboratory Medicine. 139:636‐641.
 R.M. Martinez, H.E.Ka, L.M. Scicchitano, and D.M. Wolk, Geisinger Health System, Department of Laboratory Medicine, Danville PA, Wilkes Univ., Wilkes-Barre, PA